GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Osang HealthCare Co 036220.KQ · KRW

N/A · KOSDAQ · 🇰🇷 South Korea

Compare

5,260

+3.34%

Close of 5 Nov 2026, in KRW

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩128.63bn

FY2014FY2025

Net income

₩3.11bn

FY2014FY2025

Free cash flow

−₩12.80bn

FY2014FY2025

Shareholders' equity

₩281.06bn

FY2014FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2015FY2014
Revenue₩128.63bn₩80.49bn₩355.85bn₩193.89bn₩132.33bn₩257.97bn₩50.38bn₩55.08bn
Gross profit₩57.14bn₩32.73bn₩221.11bn₩98.03bn₩47.62bn₩190.36bn₩19.70bn₩20.26bn
Research and development₩19.24bn₩20.34bn₩16.64bn₩12.11bn₩9.28bn—₩5.77bn₩7.37bn
Operating income₩3.02bn−₩24.80bn₩142.82bn₩49.26bn−₩7.08bn₩160.72bn−₩457.2m−₩4.23bn
Net income₩3.11bn−₩11.36bn₩116.44bn₩40.65bn₩1.46bn₩125.00bn−₩8.41bn−₩6.61bn
Diluted earnings per share226.09-828.828,558.912,987.86116.059,188.19-1,063.06-829.64

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2015FY2014
Total assets₩336.21bn₩295.00bn₩320.55bn₩249.18bn₩189.37bn₩244.72bn₩76.73bn₩94.87bn
Cash and short-term investments—₩9.36bn₩142.55bn₩61.14bn—₩93.13bn₩5.00bn₩2.95bn
Total liabilities₩54.89bn₩9.25bn₩27.52bn₩49.33bn₩10.90bn₩46.63bn₩24.76bn₩45.90bn
Debt₩30.24bn₩622.0m₩367.5m₩130.6m—₩2.00bn₩16.95bn₩30.87bn
Shareholders' equity₩281.06bn₩285.75bn₩293.03bn₩199.86bn₩178.46bn₩198.09bn₩51.96bn₩48.97bn
Shares outstanding14m14m14m14m13m14m8m8m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2015FY2014
Cash from operations₩6.21bn−₩38.77bn₩152.36bn₩42.53bn₩10.81bn₩101.16bn₩671.8m−₩1.33bn
Capital spending−₩19.01bn−₩13.01bn−₩35.88bn−₩11.90bn−₩9.90bn−₩7.96bn−₩2.13bn−₩3.02bn
Free cash flow−₩12.80bn−₩51.77bn₩116.48bn₩30.63bn₩908.9m₩93.20bn−₩1.46bn−₩4.36bn
Dividends paid−₩6.86bn−₩25.17bn−₩25.35bn−₩24.90bn−₩24.53bn———

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩19.14bn₩22.88bn₩28.97bn₩25.49bn₩42.03bn₩32.13bn₩19.37bn₩20.43bn
Gross profit₩5.68bn₩8.63bn₩10.81bn₩9.50bn₩20.57bn₩16.27bn₩6.17bn₩8.29bn
Operating income−₩8.08bn−₩4.39bn−₩3.19bn₩2.85bn₩1.73bn₩4.06bn−₩8.18bn−₩7.15bn
Net income−₩4.27bn−₩3.60bn−₩3.60bn₩3.01bn−₩243.4m₩3.94bn−₩1.41bn−₩5.44bn
Diluted earnings per share-310.43-261.65-261.77218.84-17.70287.13-103.16-396.95
Cash from operations₩9.71bn−₩2.82bn−₩10.46bn₩25.56bn₩1.58bn−₩10.46bn−₩38.77bn−₩34.00bn
Capital spending−₩1.69bn−₩1.17bn−₩8.62bn−₩5.35bn−₩3.59bn−₩1.44bn−₩13.01bn−₩10.02bn
Free cash flow₩8.02bn−₩3.98bn−₩19.08bn₩20.21bn−₩2.01bn−₩11.91bn−₩51.77bn−₩44.02bn
Total assets₩341.88bn₩341.78bn₩336.21bn₩340.22bn₩323.32bn₩331.30bn₩295.00bn₩287.70bn
Cash and short-term investments———————₩26.88bn
Debt₩19.65bn₩20.70bn₩30.24bn₩41.54bn₩35.06bn₩28.00bn—₩480.6m
Shareholders' equity₩279.31bn₩281.39bn₩281.06bn₩281.98bn₩275.28bn₩283.11bn₩285.75bn₩277.86bn

Financial ratios

Data as of 7 Sept 2026

FY2025FY2024FY2023FY2022FY2021
Gross margin44.4%40.7%62.1%50.6%36.0%
Operating margin2.3%-30.8%40.1%25.4%-5.4%
Net margin2.4%-14.1%32.7%21.0%1.1%
Return on equity1.1%-4.0%39.7%20.3%0.8%
Return on assets0.9%-3.9%36.3%16.3%0.8%
Revenue growth59.8%-77.4%83.5%46.5%—
Earnings growth-127.4%-109.8%186.5%2683.2%—
Current ratio4.22x7.49x6.90x3.22x10.82x
Debt to equity0.11x0.00x0.00x0.00x—
Equity ratio83.6%96.9%91.4%80.2%94.2%
Interest coverage2.72x-912.80x2423.31x1960.77x-460.55x
R&D as a share of sales15.0%25.3%4.7%6.2%7.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-12.8%-13.0%—
Operating income-60.6%-54.9%—
Net income-57.6%-52.2%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin43.0%53.9%56.3%—

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings52.4-13.7
Price to sales1.31.9

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 30 Mar 2026.

FY2026FY2024
Paid in the year200.002,500.00

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.